Vaxcyte, Inc. PCVX
We take great care to ensure that the data presented and summarized in this overview for Vaxcyte, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PCVX
View all-
Black Rock Inc. New York, NY9.94MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.03 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$936 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$866 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$485 Million0.06% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.13MShares$436 Million0.07% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD4.02MShares$425 Million0.19% of portfolio
-
State Street Corp Boston, MA3.37MShares$355 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.17MShares$335 Million0.03% of portfolio
-
Franklin Resources Inc San Mateo, CA2.46MShares$260 Million0.06% of portfolio
Latest Institutional Activity in PCVX
Top Purchases
Top Sells
About PCVX
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Insider Transactions at PCVX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 28
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,049
+1.22%
|
$65,637
$13.14 P/Share
|
|
Oct 25
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
19,108
+14.86%
|
$382,160
$20.93 P/Share
|
|
Oct 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Open market or private sale
|
Direct |
42,000
-16.7%
|
$4,830,000
$115.73 P/Share
|
|
Oct 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
42,000
+8.32%
|
$210,000
$5.35 P/Share
|
|
Oct 07
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,000
-3.1%
|
$545,000
$109.59 P/Share
|
|
Oct 07
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.95%
|
$105,000
$21.41 P/Share
|
|
Oct 07
2024
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Indirect |
7,098
-0.63%
|
$766,584
$108.97 P/Share
|
|
Oct 01
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
SELL
Open market or private sale
|
Direct |
5,500
-5.65%
|
$627,000
$114.25 P/Share
|
|
Oct 01
2024
|
Mikhail Eydelman SVP, GEN COUNSEL & CORP SEC |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+13.88%
|
$115,500
$21.41 P/Share
|
|
Oct 01
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
8,000
-1.29%
|
$912,000
$114.23 P/Share
|
|
Oct 01
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.69%
|
$16,000
$2.42 P/Share
|
|
Oct 01
2024
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
55,000
-1.32%
|
$6,270,000
$114.19 P/Share
|
|
Oct 01
2024
|
Grant Pickering CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+4.08%
|
$200,000
$5.35 P/Share
|
|
Sep 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
SELL
Open market or private sale
|
Direct |
8,000
-2.77%
|
$928,000
$116.47 P/Share
|
|
Sep 18
2024
|
Andrew Guggenhime PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+7.52%
|
$40,000
$5.35 P/Share
|
|
Sep 17
2024
|
Teri Loxam Director |
SELL
Open market or private sale
|
Direct |
6,250
-13.22%
|
$725,000
$116.02 P/Share
|
|
Sep 17
2024
|
Teri Loxam Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+31.77%
|
$137,500
$22.7 P/Share
|
|
Sep 16
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-1.59%
|
$1,160,000
$116.05 P/Share
|
|
Sep 16
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.51%
|
$20,000
$2.42 P/Share
|
|
Sep 03
2024
|
Jim Wassil CHIEF OPERATING OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
5,545
-2.67%
|
$609,950
$110.15 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 119K shares |
|---|---|
| Exercise of conversion of derivative security | 652K shares |
| Payment of exercise price or tax liability | 45.9K shares |
|---|---|
| Open market or private sale | 609K shares |
| Bona fide gift | 3.13K shares |